Introduction
tetanus toxoid-conjugate, illness
INVASIVE MENINGOCOCCAL DISEASE
Invasive meningococcal disease (IMD) is a life-threatening illness caused by the obligate human bacterium, Of the 12 meningococcal serogroups identified, 6 (A, B, C, W, Y and X) are the causative agent in the majority of cases of IMD worldwide.In the United States, the Advisory Committee on Immunization Practices (ACIP) recommends routine primary vaccination with a meningococcal conjugate vaccine (MCV4) in children aged 11 or 12 years, and a booster dose at age 16.MenACYW-TT (MenQuadfi®; Sanofi, Swiftwater, US) is a quadrivalent meningococcal polysaccharide (Serogroups A, C, W and Y) tetanus toxoid-conjugate vaccine, and does not contain an adjuvant. It was licensed in the US for use in individuals aged ≥2 years of age, and individuals aged ≥12 months in the EU, Australia, Canada, Brazil, and other countries. MenACYW-TT has been extensively evaluated in toddlers, children, adolescents and adults (including those over 65 years),The aim of this phase IIIb study was to evaluate the immunogenicity and safety of a booster dose of MenACYW-TT 3–6 years after a priming vaccination with either MenACYW-TT or MCV4-CRM (Menveo, GSK) in adolescents and adults in the US, with and without co-administration of a MenB vaccine, and to evaluate the persistence of the immune response to MenACYW-TT and MCV4-CRM 3–6 years after vaccination.